348 related articles for article (PubMed ID: 28483516)
21. ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associated miR-503/CDKN2A regulatory axis.
Li ZY; Zhu SS; Chen XJ; Zhu J; Chen Q; Zhang YQ; Zhang CL; Guo TT; Zhang LM
Biochem Biophys Res Commun; 2017 Nov; 493(2):1018-1025. PubMed ID: 28942143
[TBL] [Abstract][Full Text] [Related]
22. Aberrant expression of genes associated with stemness and cancer in endometria and endometrioma in a subset of women with endometriosis.
Ponandai-Srinivasan S; Andersson KL; Nister M; Saare M; Hassan HA; Varghese SJ; Peters M; Salumets A; Gemzell-Danielsson K; Lalitkumar PGL
Hum Reprod; 2018 Oct; 33(10):1924-1938. PubMed ID: 30020448
[TBL] [Abstract][Full Text] [Related]
23. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
[TBL] [Abstract][Full Text] [Related]
24. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
[TBL] [Abstract][Full Text] [Related]
25. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
Suda K; Cruz Diaz LA; Yoshihara K; Nakaoka H; Yachida N; Motoyama T; Inoue I; Enomoto T
Cancer Sci; 2020 Aug; 111(8):3000-3009. PubMed ID: 32473611
[TBL] [Abstract][Full Text] [Related]
26. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic inactivation of hMLH1 in the malignant transformation of ovarian endometriosis.
Ren F; Wang D; Jiang Y; Ren F
Arch Gynecol Obstet; 2012 Jan; 285(1):215-21. PubMed ID: 21556900
[TBL] [Abstract][Full Text] [Related]
28. [Tumor suppressor role of chromatin-remodeling factor ARID1A].
Guo XQ; Zhang QX; Huang WR; Duan XL; Cai ZM
Yi Chuan; 2013 Mar; 35(3):255-61. PubMed ID: 23575531
[TBL] [Abstract][Full Text] [Related]
29. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
30. Genetic, epigenetic and stem cell alterations in endometriosis: new insights and potential therapeutic perspectives.
Forte A; Cipollaro M; Galderisi U
Clin Sci (Lond); 2014 Jan; 126(2):123-38. PubMed ID: 24059589
[TBL] [Abstract][Full Text] [Related]
31. AP-1 Subunit JUNB Promotes Invasive Phenotypes in Endometriosis.
Wilson MR; Reske JJ; Chandler RL
Reprod Sci; 2022 Nov; 29(11):3266-3277. PubMed ID: 35616875
[TBL] [Abstract][Full Text] [Related]
32. [Epigenetic inactivation of SPOCK2 in the malignant transformation of ovarian endometriosis].
Ren F; Wang DB; Li T
Zhonghua Fu Chan Ke Za Zhi; 2011 Nov; 46(11):822-5. PubMed ID: 22333230
[TBL] [Abstract][Full Text] [Related]
33. Identification of differentially methylated genes in the malignant transformation of ovarian endometriosis.
Ren F; Wang DB; Li T; Chen YH; Li Y
J Ovarian Res; 2014 Jul; 7():73. PubMed ID: 25298284
[TBL] [Abstract][Full Text] [Related]
34. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
[TBL] [Abstract][Full Text] [Related]
35. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N
Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764
[TBL] [Abstract][Full Text] [Related]
36. ARID1A protein expression is retained in ovarian endometriosis with ARID1A loss-of-function mutations: implication for the two-hit hypothesis.
Yachida N; Yoshihara K; Suda K; Nakaoka H; Ueda H; Sugino K; Yamaguchi M; Mori Y; Yamawaki K; Tamura R; Ishiguro T; Isobe M; Motoyama T; Inoue I; Enomoto T
Sci Rep; 2020 Aug; 10(1):14260. PubMed ID: 32868822
[TBL] [Abstract][Full Text] [Related]
37. Potential therapeutic targets in ARID1A-mutated cancers.
Bitler BG; Fatkhutdinov N; Zhang R
Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic Alterations Affecting Transcription Factors and Signaling Pathways in Stromal Cells of Endometriosis.
Yotova I; Hsu E; Do C; Gaba A; Sczabolcs M; Dekan S; Kenner L; Wenzl R; Tycko B
PLoS One; 2017; 12(1):e0170859. PubMed ID: 28125717
[TBL] [Abstract][Full Text] [Related]
39. Cellular, histologic, and molecular changes associated with endometriosis and ovarian cancer.
Siufi Neto J; Kho RM; Siufi DF; Baracat EC; Anderson KS; Abrão MS
J Minim Invasive Gynecol; 2014; 21(1):55-63. PubMed ID: 23962574
[TBL] [Abstract][Full Text] [Related]
40. ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component.
Nishikimi K; Kiyokawa T; Tate S; Iwamoto M; Shozu M
Histopathology; 2015 Dec; 67(6):866-71. PubMed ID: 25913291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
